We are live on
!
Find out more
ABI
Adamant Biomedical Investments Portfolio holdings
AUM
$418M
This Fund
S&P 500
This Quarter
Est. Return
+5.6%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$401M
AUM Growth
–
Cap. Flow
+$398M
Cap. Flow
% of AUM
99.27%
Top 10 Holdings %
Top 10 Hldgs %
34.69%
Holding
96
New
96
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$19.2M |
| 2 |
CELG
Celgene Corp
CELG
|
+$18.7M |
| 3 |
Biogen
BIIB
|
+$18.1M |
| 4 |
CYTO
Altamira Therapeutics Ltd
CYTO
|
+$13.4M |
| 5 |
Amgen
AMGN
|
+$13.1M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 86.61% |
| 2 | Financials | 1.21% |
| 3 | Industrials | 0.33% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Gilead Sciences
GILD
$167B
| $20.9M | 5.22% |
+196,390
| New | +$19.2M |
|
|
CELG
2
DELISTED
Celgene Corp
CELG
| $19.6M | 4.89% |
+206,720
| New | +$18.7M |
|
|
3
Biogen
BIIB
$30.4B
| $18.2M | 4.54% |
+55,020
| New | +$18.1M |
|
|
4
Amgen
AMGN
$212B
| $14M | 3.51% |
+100,000
| New | +$13.1M |
|
|
AGN
5
DELISTED
Allergan plc
AGN
| $12.6M | 3.14% |
+52,110
| New | +$11.7M |
|
|
SLXP
6
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
| $12.2M | 3.05% |
+78,210
| New | +$11.3M |
|
7
UnitedHealth
UNH
$389B
| $11M | 2.76% |
+128,000
| New | +$10.8M |
|
8
Viatris
VTRS
$20.8B
| $10.5M | 2.61% |
+230,000
| New | +$11.2M |
|
|
CYTO
9
DELISTED
Altamira Therapeutics Ltd
CYTO
| $10M | 2.5% |
+27
| New | +$13.4M |
|
|
ALXN
10
DELISTED
Alexion Pharmaceuticals
ALXN
| $9.95M | 2.48% |
+60,000
| New | +$9.85M |
|
11
Medtronic
MDT
$111B
| $9.29M | 2.32% |
+150,000
| New | +$9.54M |
|
12
Abbott
ABT
$187B
| $8.32M | 2.08% |
+200,000
| New | +$8.46M |
|
13
Vertex Pharmaceuticals
VRTX
$124B
| $8.2M | 2.05% |
+73,000
| New | +$6.95M |
|
14
McKesson
MCK
$104B
| $7.98M | 1.99% |
+41,000
| New | +$7.89M |
|
15
Cardinal Health
CAH
$54.5B
| $7.87M | 1.96% |
+105,000
| New | +$7.64M |
|
|
MNK
16
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $7.21M | 1.8% |
+80,000
| New | +$6.26M |
|
17
Illumina
ILMN
$29.2B
| $7.05M | 1.76% |
+44,204
| New | +$7.39M |
|
18
Centene
CNC
$31.6B
| $6.49M | 1.62% |
+313,840
| New | +$6.05M |
|
19
Regeneron Pharmaceuticals
REGN
$72.9B
| $6.49M | 1.62% |
+18,000
| New | +$6.03M |
|
20
Teva Pharmaceuticals
TEVA
$36.9B
| $6.45M | 1.61% |
+120,000
| New | +$6.36M |
|
|
AGN
21
DELISTED
Allergan Inc
AGN
| $6.24M | 1.56% |
+35,000
| New | +$5.81M |
|
22
Molina Healthcare
MOH
$10.5B
| $5.54M | 1.38% |
+131,050
| New | +$5.8M |
|
23
Ionis Pharmaceuticals
IONS
$9.14B
| $5.44M | 1.36% |
+140,000
| New | +$4.96M |
|
|
CTRX
24
DELISTED
CATAMARAN CORP COM STK (CDA)
CTRX
| $5.25M | 1.31% |
+136,740
| New | +$6.22M |
|
25
ProShares Ultra NASDAQ Biotechnology
BIB
$84.4M
| $5.2M | 1.3% |
+100,000
| New | +$4.85M |
|
Similar funds
AGCJ
ACM
RNS
NTP
MMC
LOM
CAMI
NES
Adamant Biomedical Investments's Q3 2014 Portfolio in Review
Q3 2014 is the first quarter with a 13F filing on record for Adamant Biomedical Investments, which disclosed 96 positions worth $401M. Its ten largest holdings account for 35% of the portfolio.
Its largest position is Gilead Sciences: 196,390 shares worth $20.9M.
By sector, the portfolio is most concentrated in Healthcare at 87% of assets, followed by Financials and Industrials.
- Adamant Biomedical Investments's largest Q3 2014 buy was Gilead Sciences: 196,390 shares worth $20.9M.
- Adamant Biomedical Investments's ten largest holdings make up 35% of its $401M portfolio in Q3 2014.
- Adamant Biomedical Investments disclosed 96 positions in Q3 2014, its first 13F filing on record.
Based on Adamant Biomedical Investments's 13F filing for Q3 2014, filed 14 Nov 2014.